Geoff S Higgins
Overview
Explore the profile of Geoff S Higgins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1796
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Belan O, Sebald M, Adamowicz M, Anand R, Vancevska A, Neves J, et al.
Mol Cell
. 2022 Dec;
82(24):4664-4680.e9.
PMID: 36455556
POLQ is a key effector of DSB repair by microhomology-mediated end-joining (MMEJ) and is overexpressed in many cancers. POLQ inhibitors confer synthetic lethality in HR and Shieldin-deficient cancer cells, which...
12.
Roach J, Plaha P, McGowan D, Higgins G
J Neurooncol
. 2022 Nov;
160(3):577-589.
PMID: 36434486
Purpose: Gliomas are the most commonly occurring brain tumour in adults and there remains no cure for these tumours with treatment strategies being based on tumour grade. All treatment options...
13.
Farrer N, Higgins G, Kunkler I
Br J Cancer
. 2022 Feb;
126(9):1241-1243.
PMID: 35217798
Combined chemoradiotherapy is the standard of care for locally advanced solid tumours. However, systemic toxicity may limit the delivery of planned chemotherapy. New approaches such as radiation-induced prodrug activation might...
14.
Higgins G, Hammond E
Br J Cancer
. 2022 Feb;
126(7):971-972.
PMID: 35197582
The link between hypoxic conditions and radiation sensitivity is well-established, however the dynamic nature of hypoxia is often overlooked. The contribution of acute/transient hypoxia versus chronic conditions to radiosensitivity has...
15.
Bourigault P, Skwarski M, Macpherson R, Higgins G, McGowan D
EJNMMI Res
. 2021 Dec;
11(1):130.
PMID: 34964932
Background: Tumour hypoxia promotes an aggressive tumour phenotype and enhances resistance to anticancer treatments. Following the recent observation that the mitochondrial inhibitor atovaquone increases tumour oxygenation in NSCLC, we sought...
16.
Ruggiano A, Vaz B, Kilgas S, Popovic M, Rodriguez-Berriguete G, Singh A, et al.
Cell Rep
. 2021 Dec;
37(10):110080.
PMID: 34879279
DNA-protein crosslinks (DPCs) are a specific type of DNA lesion in which proteins are covalently attached to DNA. Unrepaired DPCs lead to genomic instability, cancer, neurodegeneration, and accelerated aging. DPC...
17.
Vivekanandan S, Fenwick J, Counsell N, Panakis N, Stuart R, Higgins G, et al.
Radiother Oncol
. 2021 Oct;
165:119-125.
PMID: 34718053
Introduction: In 'IDEAL-6' patients (N = 78) treated for locally-advanced non-small-cell lung cancer using isotoxically dose-escalated radiotherapy, overall survival (OS) was associated more strongly with V, the left atrial (LA)...
18.
Zatreanu D, Robinson H, Alkhatib O, Boursier M, Finch H, Geo L, et al.
Nat Commun
. 2021 Jun;
12(1):3636.
PMID: 34140467
To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including...
19.
Skwarski M, McGowan D, Belcher E, Di Chiara F, Stavroulias D, McCole M, et al.
Clin Cancer Res
. 2021 Feb;
27(9):2459-2469.
PMID: 33597271
Purpose: Tumor hypoxia fuels an aggressive tumor phenotype and confers resistance to anticancer treatments. We conducted a clinical trial to determine whether the antimalarial drug atovaquone, a known mitochondrial inhibitor,...
20.
Herbert K, Puliyadi R, Prevo R, Rodriguez-Berriguete G, Ryan A, Ramadan K, et al.
Cell Death Differ
. 2020 Nov;
28(4):1333-1346.
PMID: 33168956
T-LAK-originated protein kinase (TOPK) overexpression is a feature of multiple cancers, yet is absent from most phenotypically normal tissues. As such, TOPK expression profiling and the development of TOPK-targeting pharmaceutical...